Year: 2008
Type: review
Abstract: Ras proteins normally relay growth-promoting signals from many activated cell surface receptors, and they are altered by oncogenic point mutations in approximately 30% of human cancers. Activating KRAS and NRAS mutations are especially common in malignancies of the pancreas, lung, and colon, and in myeloid leukemia. Here, we discuss general strategies for targeting hyperactive Ras signaling in cancer cells with specific reference to myeloid malignancies.
Source: Clinical Cancer Research
Authors: Benjamin S. Braun, Kevin Shannon
Institution: University of California, San Francisco
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Awards: Translational Investigation of NF1 in Myeloid Luekemia, Mouse Models of Myeloid Leukemia, G5850682332, Translational Investigation of KRas & NF1 in Myeloid Leukemia, Role of PTPN11 Mutations in Myeloid Leukemogenesis, G7952510811, In Vivo Analysis of Oncogenic Kras in Leukemogenesis, G9000245133
OpenAlex ID: W2129792506
